TRPC6 and focal segmental glomerulosclerosis: Recent advancements in scRNA‐Seq technology have made it a comprehensive tool for uncovering the mechanisms of various diseases, including kidney disease.[7, 29, 30, 31] Our previous studies showed that, TRPC6 inhibition (by SH045 and genetic ablation) it ameliorates renal fibrosis and immune cell infiltration in the UUO model[12, 13] and does not appear to play a causal role in human focal segmental glomerulosclerosis (FSGS).[32] Nevertheless, the underlying mechanisms through which TRPC6 may mitigate renal fibrosis remain unknown.